RxDoctor Payments Data

Quan Nguyen, MD

Dermatology · Fountain Valley, CANPI 1760402770

Payments from drug & device makers

$17,108in general payments, 2019–2025

Across 709 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Amgen$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • UCB, Inc.$769
  • plus $5K from 20 others

What the payments were for

  • Travel & lodging$30%
  • Food & beverage$16,85799%
  • Education$2471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,108 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$158,266
Medicare patients
467
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast26$113,919
RinvoqUpadacitinib17$105,325
Taltz AutoinjectorIxekizumab14$94,770
CibinqoAbrocitinib13$71,213
OpzeluraRuxolitinib Phosphate14$28,301
Calcipotriene-BetamethasoneCalcipotriene/Betamethasone26$6,735
Fluocinonide134$5,107
Betamethasone Dipropionate105$4,790
Tacrolimus22$3,208
Clobetasol Propionate61$3,143
Ketoconazole116$2,455
Triamcinolone Acetonide237$2,314
Calcipotriene13$2,057
Metronidazole27$1,331
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip67$1,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$2,494$113,91926 claims
AbbVieRinvoq$4,695$105,32517 claims
PfizerCibinqo$1,266$71,21313 claims
Incyte CorporationOpzelura$364$28,30114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →